- Molecular NameSulindac
- SynonymNA
- Weight356.417
- Drugbank_IDDB00605
- ACS_NO38194-50-2
- Show 3D model
- LogP (experiment)3.42
- LogP (predicted, AB/LogP v2.0)3.4
- pka4.7
- LogD (pH=7, predicted)0.69
- Solubility (experiment)0.00356 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-1.89
- LogSw (predicted, AB/LogsW2.0)0.0
- Sw (mg/ml) (predicted, ACD/Labs)0.02
- No.of HBond Donors1
- No.of HBond Acceptors3
- No.of Rotatable Bonds4
- TPSA73.58
- StatusFDA approved
- AdministrationN/A
- PharmacologyA non-steroidal anti-inflammatory drug of the arylalkanoic acid class
- Absorption_value90.0
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability88.0
- Protein binding93.1
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmUndergoes two major biotransformations: reversible reduction to the sulfide metabolite, and irreversible oxidation to the sulfone metabolite. Available evidence indicates that the biological activity resides with the sulfide metabolite.
- Half life7 h, sulfide metabolite about 16 to 18 h.
- ExcretionRenal (50%) and fecal (25%)
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityCases of overdosage have been reported and rarely, deaths have occurred. The following signs and symptoms may be observed following overdosage: stupor, coma, diminished urine output and hypotension.
- LD50 (rat)LD50=264 mg/kg
- LD50 (mouse)N/A